Decoding Your Pathology Report: NEN Biology and Grading
At a Glance
The most critical part of a neuroendocrine neoplasm (NEN) pathology report is the grading, which uses the Ki-67 index and mitotic rate to show how fast the tumor is growing. The report must also distinguish between a well-differentiated NET and a poorly-differentiated NEC to guide treatment.
Your pathology report is the “blueprint” of your diagnosis. It describes the biology of your tumor and provides the data your oncology team needs to build a treatment plan. While these reports are written for doctors, you can learn to audit your report for the most critical pieces of information.
The Engines of Growth: Ki-67 and Mitotic Rate
The most important part of your report is the grading, which tells you how fast the tumor cells are dividing. Pathologists use two main measurements to determine the grade:
- Ki-67 Index: This is a percentage that represents how many cells are in the process of dividing [1][2].
- Mitotic Rate (Count): This is the number of cells actually caught in the act of dividing when the pathologist looks at a specific area of tissue (usually 2 mm²) [1][3].
Understanding the Grades
For most neuroendocrine neoplasms (NENs) in the digestive system, the grade is defined as follows:
| Grade | Ki-67 Index | Mitotic Rate | Growth Speed |
|---|---|---|---|
| Grade 1 (G1) | < 3% | < 2 | Generally slow |
| Grade 2 (G2) | 3% – 20% | 2 – 20 | Moderate |
| Grade 3 (G3) | > 20% | > 20 | Faster |
Note: In the lung, different terms like Typical Carcinoid (G1) and Atypical Carcinoid (G2) are used [4].
The G3 Distinction: NET vs. NEC
Perhaps the most critical distinction in all of NEN pathology is between a Grade 3 Well-Differentiated Neuroendocrine Tumor (G3 NET) and a Poorly-Differentiated Neuroendocrine Carcinoma (NEC) [2].
Both have a Ki-67 over 20%, but they are biologically different diseases [5]. NECs often have specific genetic changes, such as TP53 mutations or the loss of the Rb1 protein, which are rarely seen in NETs [5][6]. A G3 NET often responds to different treatments than a NEC, making this distinction vital for your care [7].
Essential Biological Markers
Your pathologist uses specialized stains called immunohistochemistry (IHC) to confirm the diagnosis. You should look for these terms on your report:
- Synaptophysin: A protein found in nearly all neuroendocrine cells; its presence confirms the tumor is neuroendocrine in origin [8][9].
- Chromogranin A (CgA): Another common marker used to identify neuroendocrine cells [8].
- Somatostatin Receptors (SSTR): These are “docking stations” on the surface of some tumor cells [10]. If your report shows SSTR2 expression (often graded from 0 to 3+), it may mean you are a candidate for specific types of imaging or targeted treatments like PRRT [10][11].
Your Report Completeness Checklist
Ensure your report includes these specific data points. If they are missing, it is worth asking your doctor why.
- [ ] Differentiation: Does it say “Well-differentiated” or “Poorly-differentiated”? [2]
- [ ] Ki-67 Index: Is there a specific percentage listed? [1]
- [ ] Mitotic Rate: Is there a count per 2 mm²? [3]
- [ ] Grade: Is it clearly stated as G1, G2, or G3? [2]
- [ ] IHC Markers: Are Synaptophysin and Chromogranin A mentioned? [8]
- [ ] SSTR Status: Is there any mention of Somatostatin Receptor expression? [10]
- [ ] Margins and Lymph Nodes: If the tumor was surgically removed, does it state if the edges were clear and if any lymph nodes were involved? [2]
Common questions in this guide
What is the Ki-67 index on a neuroendocrine tumor pathology report?
What is the difference between a G3 NET and a NEC?
What does SSTR2 expression mean on my biopsy results?
Why do NEN pathology reports test for Synaptophysin and Chromogranin A?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my pathology report clearly distinguish between a G3 NET and a NEC?
- 2.What was the Ki-67 index in my biopsy, and was it calculated manually or by an automated counter?
- 3.Was immunohistochemistry (IHC) performed for SSTR2 expression, and how does that affect my eligibility for PRRT?
- 4.If my tumor is G3, were p53 and Rb1 markers checked to help confirm the diagnosis?
- 5.Do the findings on my pathology report match the behavior seen on my PET and CT scans?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (11)
- 1
The assessment of Ki-67 for prognosis of gastroenteropancreatic neuroendocrine neoplasm patients: a systematic review and meta-analysis.
Tao Z, Xue R, Wei Z, et al.
Translational cancer research 2023; (12(8)):1980-1991 doi:10.21037/tcr-23-248.
PMID: 37701110 - 2
Aspects regarding nomenclature, classification and pathology of neuroendocrine neoplasms of the digestive system - a review.
Păun I, Becheanu G, Costin AI, et al.
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2018; (59(3)):673-678.
PMID: 30534804 - 3
Digital image analysis of Ki67 hotspot detection and index counting in gastroenteropancreatic neuroendocrine neoplasms.
Saetiew K, Angkathunyakul N, Hunnangkul S, Pongpaibul A
Annals of diagnostic pathology 2024; (71()):152295 doi:10.1016/j.anndiagpath.2024.152295.
PMID: 38547761 - 4
Head-to-head: Should Ki67 proliferation index be included in the formal classification of pulmonary neuroendocrine neoplasms?
Pelosi G, Travis WD
Histopathology 2024; (85(4)):535-548 doi:10.1111/his.15206.
PMID: 38728050 - 5
An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features.
Kasajima A, Konukiewitz B, Schlitter AM, et al.
Virchows Archiv : an international journal of pathology 2022; (480(2)):359-368 doi:10.1007/s00428-021-03202-6.
PMID: 34499237 - 6
Diagnostic relevance of p53 and Rb status in neuroendocrine tumors G3 from different organs: an immunohistochemical study of 465 high-grade neuroendocrine neoplasms.
Kanaan C, Bani MA, Ducreux M, et al.
Virchows Archiv : an international journal of pathology 2025; (486(5)):941-950 doi:10.1007/s00428-024-04006-0.
PMID: 39671088 - 7
Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A, Maisonneuve P, Prinzi N, et al.
Neuroendocrinology 2020; (110(7-8)):616-629 doi:10.1159/000503722.
PMID: 31557757 - 8
Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts.
González I, Lu HC, Sninsky J, et al.
Histopathology 2019; (75(4)):568-577 doi:10.1111/his.13899.
PMID: 31077609 - 9
Insulinoma-associated protein-1 (INSM-1) is a useful diagnostic marker for the evaluation of primary thymic neuroendocrine neoplasms: an immunohistochemical study of 27 cases.
Suster D, Chacko D, VanderLaan P, et al.
Virchows Archiv : an international journal of pathology 2025; (486(4)):721-727 doi:10.1007/s00428-024-03904-7.
PMID: 39223347 - 10
Advances in Molecular Imaging for Neuroendocrine Neoplasms.
Girod B, Prasad V
Cancers 2025; (17(12)) doi:10.3390/cancers17122013.
PMID: 40563663 - 11
Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors.
Njotu FN, Pougoue Ketchemen J, Babeker H, et al.
European journal of nuclear medicine and molecular imaging 2025; (52(4)):1305-1320 doi:10.1007/s00259-024-07011-2.
PMID: 39627348
This page explains NEN pathology terminology for educational purposes only. Your pathologist and oncologist are the best sources for interpreting your specific biopsy results and tumor grade.
Get notified when new evidence is published on Neuroendocrine neoplasm.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.